Recent Posts
- Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update November 13, 2023
- Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production November 3, 2023
- Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program October 30, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com
Eyenovia’s Presentation at the Ladenburg Thalmann Healthcare Conference Wednesday July 14, 2021
NewsEyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
NewsEyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
NewsEyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
NewsEyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
NewsEyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
NewsEyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
NewsEYENOVIA TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS ON THURSDAY, MARCH 25
NewsEyenovia to Participate in the 33rd Annual Roth Conference
NewsEyenovia Announces FDA Acceptance of the MydCombi NDA
News